Browse by Phase
Phase 2 / Phase 3 Clinical Trials
Phase 2/3 combined trials bridge efficacy assessment and large-scale comparison, enrolling larger cohorts while still gathering dose-response data.
Total Trials
122
Recruiting Now
122
Top Conditions in Phase 2 / Phase 3
Gastric Cancer (2) Pancreatic Ductal Adenocarcinoma (2) Breast Cancer (2) Non-Squamous Non-Small Cell Lung Cancer (2) Primary Central Nervous System Lymphoma (2) Multiple Myeloma (2) HCC (2) Heart Failure (2) Acute Myeloid Leukemia (2) Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia (B-ALL) (1)
Frequently Asked Questions — Phase 2 / Phase 3 Trials
What distinguishes a Phase 2/3 combined trial?
Phase 2/3 combined trials bridge efficacy assessment and large-scale comparative confirmation in a single expanding protocol. The Phase 2 portion identifies optimal dosing and collects early efficacy signals, while the Phase 3 portion expands enrollment and applies the primary statistical analysis to a larger population. This design reduces time from dose selection to pivotal evidence.
How large are Phase 2/3 combined trials?
Phase 2/3 trials are larger than standalone Phase 2 studies but may be smaller than fully powered Phase 3 trials. Enrollment typically ranges from 200 to 1,000 participants, depending on the condition, endpoint, and statistical requirements. Interim analyses allow sample size adjustment if early results indicate more statistical power is needed.
Who benefits most from Phase 2/3 trial designs?
Phase 2/3 designs particularly benefit patients with serious or rare conditions where standard treatments are inadequate. Because the Phase 2 and Phase 3 portions run as one continuous protocol, patients who enroll in Phase 2 may transition into the Phase 3 portion without interruption—a continuity of care advantage compared to sequential separate studies.
Active Phase 2 / Phase 3 Studies
NCT07583888 Phase 2, Phase 3
Recruiting
VABu Conditioning in Elderly AML HSCT
Condition
Allogeneic Hematopoietic Stem Cell Transplantation Recipient
Enrollment
20 pts
Location
China
Sponsor
The First Affiliated Hospital
NCT03804931 Phase 2, Phase 3
Recruiting
Fecal Microbiota Transplantation for Ulcerative Colitis
Condition
Ulcerative Colitis
Enrollment
120 pts
Location
China
Sponsor
Guangzhou First People's Hospi
NCT06740903 Phase 2, Phase 3
Recruiting
Evaluating Perioperative Outcomes: Dexmedetomidine vs Lignocaine in Laparoscopic...
Condition
Hemodynamics Instability
Enrollment
140 pts
Location
Pakistan
Sponsor
Sahiwal medical college sahiwa
NCT06125327 Phase 2, Phase 3
Recruiting
SC1011 Twice Daily vs Placebo in Patients Diagnosed With Idiopathic Pulmonary Fi...
Condition
Idiopathic Pulmonary Fibrosis
Enrollment
210 pts
Location
China
Sponsor
Guangzhou JOYO Pharma Co., Ltd
NCT07242456 Phase 2, Phase 3
Recruiting
Head-to-head Study of Tegoprazan 50 mg BID Plus Amoxicillin 1 g TID vs. Vonopraz...
Condition
Helicobacter Pylori Infection
Enrollment
240 pts
Location
China
Sponsor
First People's Hospital of Han
NCT07537998 Phase 2, Phase 3
Recruiting
Antegrade Intestinal Fluid Reinfusion for Prevention of Low Anterior Resection S...
Condition
Low Anterior Resection Syndrome
Enrollment
160 pts
Location
China
Sponsor
Pei-Rong Ding
NCT06768840 Phase 2, Phase 3
Recruiting
Vitiligo, New Treatment and Serum s100B
Condition
Vitiligo, Generalized
Enrollment
50 pts
Location
Egypt
Sponsor
South Valley University
NCT07163611 Phase 2, Phase 3
Recruiting
Obinutuzumab Induced Decreases of PLA2R Antibodies in Membranous Nephropathy: a ...
Condition
Membranous Nephropathy - PLA2R Induced
Enrollment
20 pts
Location
Netherlands
Sponsor
Radboud University Medical Cen
NCT06212336 Phase 2, Phase 3
Recruiting
ISTH/ANRS 0409s INTEGRATE Lassa Fever Study
Condition
Lassa Fever
Enrollment
1,755 pts
Location
Liberia, Nigeria
Sponsor
Irrua Specialist Teaching Hosp
NCT05678621 Phase 2, Phase 3
Recruiting
Role of Antibiotic Therapy or Immunoglobulin On iNfections in hAematoLogy: Immun...
Condition
Haematological Malignancy
Enrollment
300 pts
Location
Australia
Sponsor
Monash University
NCT02448992 Phase 2, Phase 3
Recruiting
Hippocampal-Sparing Prophylactic Cranial Irradiation in Pathologically Nodal Pos...
Condition
Non-Small-Cell Lung Cancer (NSCLC)
Enrollment
90 pts
Location
Taiwan
Sponsor
Chang Gung Memorial Hospital
NCT07310758 Phase 2, Phase 3
Recruiting
Contrast-enhanced Ultrasound for Sentinel Node Detection
Condition
Melanoma
Enrollment
91 pts
Location
Netherlands
Sponsor
The Netherlands Cancer Institu
NCT05418244 Phase 2, Phase 3
Recruiting
Inhaled Isopropyl Alcohol for Treatment of Nausea
Condition
Vomiting
Enrollment
84 pts
Location
United States
Sponsor
State University of New York a
NCT07391306 Phase 2, Phase 3
Recruiting
The Study is Being Conducted to Find a New Treatment for Patients Suffering From...
Condition
IC
Enrollment
180 pts
Location
Russia
Sponsor
JSC NextGen
NCT04654338 Phase 2, Phase 3
Recruiting
2 Ablative RadioTherapy Treatments for Prostate Cancer
Condition
Prostate Cancer
Enrollment
30 pts
Location
Canada
Sponsor
Sunnybrook Health Sciences Cen
NCT06706544 Phase 2, Phase 3
Recruiting
Ozone Treatment in Paresthesia (Numbness, Tingling) Secondary to Chemotherapy-in...
Condition
Chemotherapy Induced Peripheral Neuropathy (CIPN)
Enrollment
42 pts
Location
Spain
Sponsor
Bernardino Clavo, MD, PhD
NCT04616781 Phase 2, Phase 3
Recruiting
Ketone Ester Intervention in Alcohol Use Disorder
Condition
Alcohol Drinking
Enrollment
20 pts
Location
United States
Sponsor
University of Pennsylvania
NCT05255302 Phase 2, Phase 3
Recruiting
De-escalation Immunotherapy mAintenance Duration Trial for Stage IV Lung Cancer ...
Condition
Metastatic NSCLC
Enrollment
1,360 pts
Location
France
Sponsor
Intergroupe Francophone de Can
NCT07063745 Phase 2, Phase 3
Recruiting
A Study to Compare the Combination of Navlimetostat (BMS-986504) With Pembrolizu...
Condition
Metastatic Non-small Cell Lung Cancer With MTAP Deletion
Enrollment
590 pts
Location
United States, Argentina, Australia
Sponsor
Bristol-Myers Squibb
NCT04333537 Phase 2, Phase 3
Recruiting
Comparing Sentinel Lymph Node (SLN) Biopsy With Standard Neck Dissection for Pat...
Condition
Buccal Mucosa Squamous Cell Carcinoma
Enrollment
686 pts
Location
United States, Canada
Sponsor
NRG Oncology
NCT07319897 Phase 2, Phase 3
Recruiting
68Ga-BCMA PET/CT in Multiple Myeloma
Condition
Multiple Myeloma
Enrollment
300 pts
Location
China
Sponsor
Peking University First Hospit
NCT06674148 Phase 2, Phase 3
Recruiting
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of the Efficac...
Condition
Interstitial Lung Disease
Enrollment
124 pts
Location
China
Sponsor
Huilan Zhang
NCT05833815 Phase 2, Phase 3
Recruiting
Addition of Everolimus to Standard of Care in Carcinoma Gallbladder
Condition
Gallbladder Cancer
Enrollment
56 pts
Location
India
Sponsor
Banaras Hindu University
NCT06970626 Phase 2, Phase 3
Recruiting
Quality of Recovery in Laparoscopic Sleeve Gastrectomy Using Dexmedetomidine Inf...
Condition
Laparoscopic Sleeve Gastrectomy
Enrollment
60 pts
Location
Egypt
Sponsor
Alexandria University
NCT07441876 Phase 2, Phase 3
Recruiting
Study to Evaluate the Efficacy and Safety of BMN 333 Versus Vosoritide in Childr...
Condition
Achondroplasia
Enrollment
160 pts
Location
United States, Australia, Italy
Sponsor
BioMarin Pharmaceutical
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer · Last Reviewed: April 2026 · Data Methodology